Meta-iodobenzyl guanidine for detection and staging of neuroendocrine tumors

Nuclear Medicine and Biology

Volumn 35, Issue SUPPL.1, 2008, Pages

  Pryma, Daniel ^a   Divgi, Chaitanya ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Iodine 123; MIBG; NET

Indexed keywords

(3 IODOBENZYL)GUANIDINE; (3 IODOBENZYL)GUANIDINE I 123; (3 IODOBENZYL)GUANIDINE I 131; FLUORODEOXYGLUCOSE; IODINE 124; NORADRENALIN TRANSPORTER; POTASSIUM IODIDE; SOMATOSTATIN RECEPTOR; TRACER;

CAMERA; CANCER STAGING; CARCINOID; CHILDHOOD CANCER; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DOSIMETRY; DRUG UPTAKE; GASTROINTESTINAL TUMOR; GLYCOLYSIS; HUMAN; IMAGING; LETHALITY; NEUROBLASTOMA; NEUROENDOCRINE TUMOR; PANCREAS TUMOR; PARAGANGLIOMA; PHENOTYPE; PHEOCHROMOCYTOMA; POSITRON EMISSION TOMOGRAPHY; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TUMOR DIAGNOSIS;

EID: 49049103729     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2008.06.004     Document Type: Review

References (36)

1. Kolby L., Bernhardt P., Levin-Jakobsen A.M., et al. Uptake of metaiodobenzylguanidine in neuroendocrine tumors is mediated by vesicular monoamine transporters. Br J Cancer 89 (2003) 1383-1388
2. Wafelman A.R., Hoefnagel C.A., Maes R.A.A., et al. Radioiodinated metaiodobenzylguanidine: a review of its biodistribution and pharmacokinetics, drug interaction, cytotoxicity and dosimetry. Eur J Nucl Med 21 (1994) 545-559
3. Rufini V., Calcagni M.L., and Baum R.P. Imaging of neuroendocrine tumors. Semin Nucl Med 36 (2006) 228-247
4. 131I-MIBG: evaluation of a therapeutic preparation. J Nucl Med 36 (1995) 1088-1095
5. 123I-MIBG: an initial clinical study in patients with phaeochromocytoma. Nucl Med Commun 21 (2000) 437-440
6. Schillaci O. Functional-anatomic image fusion in neuroendocrine tumors. Cancer Biother Radiopharm 19 (2004) 129-134
7. Bonnin F., Lumbroso J., Tenebaum F., et al. Refining interpretation of MIBG scans in children. J Nucl Med 35 (1994) 803-810
8. 123I- metaiodobenzylguanidine in the contralateral adrenal region after resection of an adrenal pheochromocytoma. N Engl J Med 342 (2000) 1450-1451
9. 123I- metaiodobenzylguanidine uptake in the nape of the neck of children: likely visualization of brown adipose tissue. J Nucl Med 44 (2003) 141-145
10. 123I-MIBG uptake in the neck and shoulders of a neuroblastoma patient: damage to sympathetic innervation blocks uptake in brown adipose tissue. Pediatr Radiol 34 (2004) 577-579
11. Leung A., Shapiro B., Hattner R., et al. The specificity of radioiodinated MIBG for neural crest tumors in childhood. J Nucl Med 38 (1997) 1352-1357
12. Modlin I.M., Oberg K., Chung S.C., et al. Gastronteropancreatic neuroendocrine tumours. Lancet Oncol 9 (2008) 61-72
13. Klingler H.C., Klingler P.J., Martin Jr. J.K., et al. Pheochromocytoma. Urology 57 (2001) 1025-1032
14. Mantero F., Terzolo M., Arnaldi G., et al. A survey on adrenal incidentaloma in Italy. Study group on adrenal tumors of the Italian Society of Endocrinology. J Clin Endocrinol Metab 85 (2000) 637-644
15. Pacak K., Linehan W.M., Eisenhofer G., et al. Recent advances in genetics, diagnosis, localization and treatment of pheochromocytoma. Ann Intern Med 134 (2001) 315-329
16. Pomares F.J., Canas R., Rodriguez J.M., et al. Differences between sporadic and multiple endocrine neoplasia type 2A pheochromocytoma. Clin Endocrinol 48 (1998) 195-200
17. McEwan A.J., Shapiro B., Sisson J.C., et al. Radioiodobenzylguanidine for the scintigraphic location and therapy of adrenergic tumors. Semin Mucl Med 5 (1985) 132-135
18. Troncone L., Rufini V., Montemaggi P., et al. The diagnostic and therapeutic utility of radioiodinated metaiodobenzylguanidine (MIBG): 5 years of experience. Eur J Nucl Med 16 (1990) 325-335
19. Maurea S., Cuocolo A., Reynolds J.C., et al. Iodine-131-metaiodobenzylguanidine scintigraphy in preoperative and post-operative evaluation of paragangliomas: comparison with CT and MRI. J Nucl Med 34 (1993) 173-179
20. Jalil N.D., Pattou F.N., Combemale F., et al. Effectiveness and limits of preoperative imaging studies for the localisation of pheochromocytomas and paragangliomas: a review of 282 cases. French Association of Surgery (AFC) and the French Association of Endocrine Surgeons (AFCE). Eur J Surg 164 (1998) 23-28
21. Troncone L., and Rufini V. MIBG in diagnosis of neuroendocrine tumors. In: Ell P.J., and Gambhir S.S. (Eds). Nuclear Medicine in clinical diagnosis and treatment Vol. 1 (2004), Churchill Livingstone, Edinburgh 83-95
22. Guller Y., Turek J Eubanks S., et al. Detecting pheochromocytoma: detecting the most sensitive test. Ann Surg 243 (2006) 102-107
23. Furuta N., Kyota H., Yoshigoe F., et al. Diagnosis of pheochromocytoma using [123I]- metaiodobenzylguanidine compared to [131I]- metaiodobenzylguanidine scintigraphy. Int J Urol 6 (1999) 119-124
24. Oberg K. State of the art and future prospects in the management of neuroendocrine tumors. Q J Nucl Med 44 (2000) 3-12
25. Seregni E., Ferrari L., Stivanello M., et al. Laboratory tests for neuroendocrine tumours. Q J Nucl Med 44 (2000) 22-41
26. Jensen R.T. Carcinoid and pancreatic endocrine tumors: recent advances in molecular pathogenesis, localization and treatment. Curr Opin Oncol 12 (2000) 368-377
27. Maris J.M., Hogarty M.D., Bagatell R., et al. Neuroblastoma. Lancet 369 (2007) 2106-2120
28. Matthay K.K., Yanik G., Messina J., et al. Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastoma. J Clin Oncol 25 (2007) 1054-1060
29. Olivier P., Colarinha P., Fettich J., et al. Guidelines for radioiodinated MIBG scintigraphy in children. Eur J Nucl Med Mol Imaging 30 (2003) B45-B50
30. Kayani I., Bomanji J.B., Groves A., et al. Functional imaging of neuroendocrine tumors with combined PET/CT using (68)Ga-DOTATATE (DOTA-DPhe(1),Tyr(3)-octreotate) and (18)F-FDG. Cancer 112 (2008) 2447-2455
31. Koopmans K.P., Neels O.C., Kema I.P., et al. Improved staging of patients with carcinoid and islet cell tumors with 18F-dihydroxy-phenyl-alanine and 11C-5-hydroxy-tryptophan positron emission tomography. J Clin Oncol 26 (2008) 1489-1495
32. Vaidyanathan G., Affleck D.J., Alston K.L., et al. A kit method for the high level synthesis of [211At]MABG. Bioorg Med Chem 15 (2007) 3430-3436
33. Divgi C.R., Pandit-Taskar N., Jungbluth A.A., et al. Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trial. Lancet Oncol 8 (2007) 304-310
34. Hoegerle S., Nitzsche E., Altehoefer C., Ghanem N., Manz T., Brink I., Reincke M., et al. Pheochromocytomas: detection with 18F DOPA whole body PET - initial results. Radiology 222 (2002) 507-512
35. Jager P.L., Chirakal R., Marriott C.J., Brouwers A.H., Koopmans K.P., and Gulenchyn K.Y. 6-l-18F-Fluorodihydroxyphenylalanine PET in neuroendocrine tumors: basic aspects and emerging clinical applications. J Nucl Med 49 (2008) 573-586
36. Jentzen W., Weise R., Kupferschläger J., et al. Iodine-124 PET dosimetry in differentiated thyroid cancer: recovery coefficient in 2D and 3D modes for PET(/CT) systems. Eur J Nucl Med Mol Imaging 35 (2008) 611-623